These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10935056)

  • 1. Mutation causes sensitivity.
    AIDS Patient Care STDS; 2000 Jul; 14(7):395. PubMed ID: 10935056
    [No Abstract]   [Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Zachary KC; Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
    Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
    AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
    Paulsen D; Elston R; Snowden W; Tisdale M; Ross L
    J Antimicrob Chemother; 2003 Sep; 52(3):319-23. PubMed ID: 12917233
    [No Abstract]   [Full Text] [Related]  

  • 6. Amprenavir may be less cross-resistant with other PIs.
    Murphy MJ
    HIV Clin; 1999; 11(5):1, 7. PubMed ID: 11810849
    [No Abstract]   [Full Text] [Related]  

  • 7. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Lam E; Parkin NT
    Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
    [No Abstract]   [Full Text] [Related]  

  • 8. [Resistance to protease inhibitors].
    Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
    [No Abstract]   [Full Text] [Related]  

  • 9. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
    Scudeller L; Torti C; Quiros-Roldan E; Patroni A; Lo Caputo S; Moretti F; Mazzotta F; Donati E; Vivarelli A; Carosi G;
    J Antimicrob Chemother; 2003 Nov; 52(5):776-81. PubMed ID: 14563897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
    Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
    J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
    [No Abstract]   [Full Text] [Related]  

  • 13. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 14. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?
    Aizawa S; Gatanaga H; Ida S; Sakai A; Tanaka M; Takahashi Y; Hirabayashi Y; Oka S
    AIDS; 1999 Jul; 13(10):1278-9. PubMed ID: 10416536
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Murphy MD; Marousek GI; Chou S
    J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amprenavir (Agenerase).
    Res Initiat Treat Action; 2000 Mar; 6(1):32-3. PubMed ID: 11708186
    [No Abstract]   [Full Text] [Related]  

  • 18. No inherent association between minor mutations in HIV protease at baseline and selection of the L90M mutation at the time of the first virological failure.
    Brumme CJ; Harrigan PR
    J Infect Dis; 2005 May; 191(10):1778-9; author reply 1779-80. PubMed ID: 15838807
    [No Abstract]   [Full Text] [Related]  

  • 19. Human immunodeficiency virus. Protease uninhibited.
    Richman DD
    Nature; 1995 Apr; 374(6522):494. PubMed ID: 7700370
    [No Abstract]   [Full Text] [Related]  

  • 20. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
    Stürmer M; Staszewski S; Doerr HW; Hertogs K
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):967-8. PubMed ID: 14678603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.